Surface-modified hydroxyapatite nanoparticle for microRNA delivery to regulate gene expression in human mandibular osteoblast cells
Source abstract
Abstract
Hydroxyapatite nanoparticles (HA-NPs) are proposed for a miRNA delivery system with additional value in bone engineering because of its osteogenic activity. HA-NPs were synthesized by hydrothermal method, and surface-modified with two cationic functional groups 3-aminopropyltriethoxysilane (HA-NPs-APTES) and poly2-(dimethylamino)ethyl methacrylate (HA-NPs-PDMAEMA). The particles were visualized under a transmission electron microscope and then characterized for their physical properties, cell compatibility, and efficiency of miRNA binding. The FitC-tagged particles internalized in human mandibular osteoblasts (HMOBs) demonstrated insufficient miRNA binding and internalization of the unmodified particles. HA-NPs-APTES particles were in 150–200 nm elongated shape and demonstrated positive surface charge with the highest miRNA binding efficiency. HA-NPs-APTES was highly internalized in HMOBs without significantly changing cell metabolism. In contrast, PDMAEMA-modified particles demonstrated an increase in size and surface charge, and are thus potentially toxic to cells. The level of delivered miRNA in total RNA was determined by qPCR, and the HA-NP delivery system was analyzed. The HA-NP delivery system efficiently delivered miRNA, and the miRNA-targeted GAPDH expression was diminished by three- to tenfold. The GAPDH level was suppressed after 50 μg/mL or 100 μg/mL HA-NPs-APTES, significantly lower than the effect by Dharmafect. In conclusion, HA-NPs-APTES demonstrates optimal efficiency in miRNA delivery and gene regulation in the osteoblast in vitro model.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Bone Tissue Engineering Materials · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. Bai H, Lester GMS, Petishnok LC, Dean DA (2017) Cytoplasmic transport and nuclear import of plasmid DNA. Biosci Rep 37. https://doi.org/10.1042/BSR2016061610.1042/BSR20160616 ↗
2. Barradas AMC, Yuan H, van Blitterswijk CA, Habibovic P (2011) Osteoinductive biomaterials: current knowledge of properties, experimental models and biological mechanisms. Eur Cell Mater 21:407–429; discussion 429. https://doi.org/10.22203/ecm.v021a3110.22203/ecm.v021a31 ↗
3. Cai Q, Zhu Y, He JQ, Wang ZH, Su F, Xu FJ, Yang XP, Yang WT (2012) Well-defined hydroxyapatite–polycation nanohybrids via surface-initiated atom transfer radical polymerization for biomedical applications. J Mater Chem 22:9358–9367. https://doi.org/10.1039/c2jm31109g10.1039/c2jm31109g ↗
4. Chen Y, Gao D-Y, Huang L (2015) In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev 81:128–141. https://doi.org/10.1016/j.addr.2014.05.00910.1016/j.addr.2014.05.009 ↗
5. Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, Saltzman WM, Slack FJ (2015) MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518(7537):107–11010.1038/nature13905 ↗
6. Fabbri M, Paone A, Calore F, Galli R, Croce CM (2013) A new role for microRNAs, as ligands of toll-like receptors. RNA Biol 10:169–174. https://doi.org/10.4161/rna.2314410.4161/rna.23144 ↗
7. Fröhlich E (2012) The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine 7:5577–5591. https://doi.org/10.2147/IJN.S3611110.2147/IJN.S36111 ↗
8. Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U, Manygoats K, Seifert S, Andree C, Stöter M, Epstein-Barash H, Zhang L, Koteliansky V, Fitzgerald K, Fava E, Bickle M, Kalaidzidis Y, Akinc A, Maier M, Zerial M (2013) Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol 31:638–646. https://doi.org/10.1038/nbt.261210.1038/nbt.2612 ↗
9. Glinge C, Clauss S, Boddum K, Jabbari R, Jabbari J, Risgaard B, Tomsits P, Hildebrand B, Kääb S, Wakili R, Jespersen T, Tfelt-Hansen J (2017) Stability of circulating blood-based MicroRNAs - pre-analytic methodological considerations. PLoS One 12:e0167969. https://doi.org/10.1371/journal.pone.016796910.1371/journal.pone.0167969 ↗
10. Granot Y, Peer D (2017) Delivering the right message: challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-an innate immune system standpoint. Semin Immunol 34:68–77. https://doi.org/10.1016/j.smim.2017.08.01510.1016/j.smim.2017.08.015 ↗
11. Hadas Y, Sultana N, Youssef E, Sharkar MTK, Kaur K, Chepurko E, Zangi L (2019) Optimizing modified mRNA in vitro synthesis protocol for heart gene therapy. Mol Ther Methods Clin Dev 14:300–305. https://doi.org/10.1016/j.omtm.2019.07.00610.1016/j.omtm.2019.07.006 ↗
12. Huntzinger E, Izaurralde E (2011) Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 12:99–11010.1038/nrg2936 ↗
13. Irwandi RA, Khonsuphap P, Limlawan P, Vacharaksa A (2018) miR-302a-3p regulates RANKL expression in human mandibular osteoblast-like cells. J Cell Biochem 119:4372–4381. https://doi.org/10.1002/jcb.2645610.1002/jcb.26456 ↗
14. Kapadia CH, Ioele SA, Day ES (2020a) Layer-by-layer assembled PLGA nanoparticles carrying miR-34a cargo inhibit the proliferation and cell cycle progression of triple-negative breast cancer cells. J Biomed Mater Res A 108:601–613. https://doi.org/10.1002/jbm.a.3684010.1002/jbm.a.36840 ↗
15. Kapadia CH, Luo B, Dang MN, Irvin-Choy ND, Valcourt DM, Day ES (2020b) Polymer nanocarriers for MicroRNA delivery. J Appl Polym Sci 25:48651. https://doi.org/10.1002/app.4865110.1002/app.48651 ↗
16. Kim TK, Eberwine JH (2010) Mammalian cell transfection: the present and the future. Anal Bioanal Chem 397:3173–3178. https://doi.org/10.1007/s00216-010-3821-610.1007/s00216-010-3821-6 ↗
17. Kimura T, Nibe Y, Funamoto S, Okada M, Furuzono T, Ono T, Yoshizawa H, Fujisato T, Nam K, Kishida A (2011) Preparation of a nanoscaled poly(vinyl alcohol)/hydroxyapatite/DNA complex using high hydrostatic pressure technology for in vitro and in vivo gene delivery. J Drug Deliv 2011:962743–962748. https://doi.org/10.1155/2011/96274310.1155/2011/962743 ↗
18. Köberle V, Pleli T, Schmithals C, Augusto Alonso E, Haupenthal J, Bönig H, Peveling-Oberhag J, Biondi RM, Zeuzem S, Kronenberger B, Waidmann O, Piiper A (2013) Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS One 8:e75184. https://doi.org/10.1371/journal.pone.007518410.1371/journal.pone.0075184 ↗
19. Künnapuu K, Veiman K-L, Porosk L, Rammul E, Kiisholts K, Langel Ü, Kurrikoff K (2019) Tumor gene therapy by systemic delivery of plasmid DNA with cell-penetrating peptides. FASEB Bioadv 1:105–114. https://doi.org/10.1096/fba.102610.1096/fba.1026 ↗
20. Li J, Xue S, Mao Z-W (2016) Nanoparticle delivery systems for siRNA-based therapeutics. J Mater Chem B 4:6620–6639. https://doi.org/10.1039/C6TB01462C10.1039/C6TB01462C ↗
21. Ma D (2014) Enhancing endosomal escape for nanoparticle mediated siRNA delivery. Nanoscale 6:6415–6425. https://doi.org/10.1039/c4nr00018h10.1039/c4nr00018h ↗
22. Mencía Castaño I, Curtin CM, Shaw G et al (2015) A novel collagen-nanohydroxyapatite microRNA-activated scaffold for tissue engineering applications capable of efficient delivery of both miR-mimics and antagomiRs to human mesenchymal stem cells. J Control Release 200:42–51. https://doi.org/10.1016/j.jconrel.2014.12.03410.1016/j.jconrel.2014.12.034 ↗
23. Muthiah M, Park I-K, Cho C-S (2013) Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics. Expert Opin Drug Deliv 10:1259–1273. https://doi.org/10.1517/17425247.2013.79864010.1517/17425247.2013.798640 ↗
24. Okazaki M, Yoshida Y, Yamaguchi S, Kaneno M, Elliott JC (2001) Affinity binding phenomena of DNA onto apatite crystals. Biomaterials 22:2459–2464. https://doi.org/10.1016/s0142-9612(00)00433-610.1016/s0142-9612(00)00433-6 ↗
25. Peng L-H, Niu J, Zhang C-Z, Yu W, Wu JH, Shan YH, Wang XR, Shen YQ, Mao ZW, Liang WQ, Gao JQ (2014) TAT conjugated cationic noble metal nanoparticles for gene delivery to epidermal stem cells. Biomaterials 35:5605–5618. https://doi.org/10.1016/j.biomaterials.2014.03.06210.1016/j.biomaterials.2014.03.062 ↗
26. Rather HA, Jhala D, Vasita R (2019) Dual functional approaches for osteogenesis coupled angiogenesis in bone tissue engineering. Mater Sci Eng C Mater Biol Appl 103:109761. https://doi.org/10.1016/j.msec.2019.10976110.1016/j.msec.2019.109761 ↗
27. Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16:203–222. https://doi.org/10.1038/nrd.2016.24610.1038/nrd.2016.246 ↗
28. Russo L, Taraballi F, Lupo C, Poveda A, Jiménez-Barbero J, Sandri M, Tampieri A, Nicotra F, Cipolla L (2014) Carbonate hydroxyapatite functionalization: a comparative study towards (bio)molecules fixation. Interface Focus 4:20130040. https://doi.org/10.1098/rsfs.2013.004010.1098/rsfs.2013.0040 ↗
29. Sahin U, Karikó K, Türeci Ö (2014) mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov 13:759–780. https://doi.org/10.1038/nrd427810.1038/nrd4278 ↗
30. Scholz C, Wagner E (2012) Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. J Control Release 161:554–565. https://doi.org/10.1016/j.jconrel.2011.11.01410.1016/j.jconrel.2011.11.014 ↗
31. Shirley JL, de Jong YP, Terhorst C, Herzog RW (2020) Immune responses to viral gene therapy vectors. Mol Ther 28:709–722. https://doi.org/10.1016/j.ymthe.2020.01.00110.1016/j.ymthe.2020.01.001 ↗
32. Sun J, Zheng X, Li H, Fan D, Song Z, Ma H, Hua X, Hui J (2017) Monodisperse selenium-substituted hydroxyapatite: controllable synthesis and biocompatibility. Mater Sci Eng C Mater Biol Appl 73:596–602. https://doi.org/10.1016/j.msec.2016.12.10610.1016/j.msec.2016.12.106 ↗
33. Tseng Y-C, Mozumdar S, Huang L (2009) Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 61:721–731. https://doi.org/10.1016/j.addr.2009.03.00310.1016/j.addr.2009.03.003 ↗
34. Uskoković V, Uskoković DP (2011) Nanosized hydroxyapatite and other calcium phosphates: chemistry of formation and application as drug and gene delivery agents. J Biomed Mater Res Part B Appl Biomater 96:152–191. https://doi.org/10.1002/jbm.b.3174610.1002/jbm.b.31746 ↗
35. Varkouhi AK, Scholte M, Storm G, Haisma HJ (2011) Endosomal escape pathways for delivery of biologicals. J Control Release 151:220–228. https://doi.org/10.1016/j.jconrel.2010.11.00410.1016/j.jconrel.2010.11.004 ↗
36. Wang L, Zhang L (2020) Circulating exosomal miRNA as diagnostic biomarkers of neurodegenerative diseases. Front Mol Neurosci 13:53. https://doi.org/10.3389/fnmol.2020.0005310.3389/fnmol.2020.00053 ↗
37. Wang X, Li X, Ito A, Watanabe Y, Tsuji NM (2016a) Rod-shaped and fluorine-substituted hydroxyapatite free of molecular immunopotentiators stimulates anti-cancer immunity in vivo. Chem Commun (Camb) 52:7078–7081. https://doi.org/10.1039/c6cc02848a10.1039/c6cc02848a ↗
38. Wang X, Li X, Ito A, Watanabe Y, Sogo Y, Hirose M, Ohno T, Tsuji NM (2016b) Rod-shaped and substituted hydroxyapatite nanoparticles stimulating type 1 and 2 cytokine secretion. Colloids Surf B: Biointerfaces 139:10–16. https://doi.org/10.1016/j.colsurfb.2015.12.00410.1016/j.colsurfb.2015.12.004 ↗
39. Yamamoto A, Kormann M, Rosenecker J, Rudolph C (2009) Current prospects for mRNA gene delivery. Eur J Pharm Biopharm 71:484–489. https://doi.org/10.1016/j.ejpb.2008.09.01610.1016/j.ejpb.2008.09.016 ↗
40. Yang N (2015) An overview of viral and nonviral delivery systems for microRNA. Int J Pharm Investig 5:179–181. https://doi.org/10.4103/2230-973X.16764610.4103/2230-973X.167646 ↗
41. Zhang Y, Wang Z, Gemeinhart RA (2013) Progress in microRNA delivery. J Control Release 172:962–974. https://doi.org/10.1016/j.jconrel.2013.09.01510.1016/j.jconrel.2013.09.015 ↗
42. Zhao L, Zhao W, Liu Y et al (2017) Nano-hydroxyapatite-derived drug and gene co-delivery system for anti-angiogenesis therapy of breast Cancer. Med Sci Monit 23:4723–4732. https://doi.org/10.12659/msm.90253810.12659/msm.902538 ↗